The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Official Title: A Phase II, Multicenter, Single-Arm Clinical Trial of Radiotherapy and CeMiPlimAb: Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
Study ID: NCT05574101
Brief Summary: The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Colorado (Data Collection Only), Aurora, Colorado, United States
Moffitt Cancer Center (Data Collection Only), Tampa, Florida, United States
Emory University, Atlanta, Georgia, United States
Memorial Sloan Kettering Cancer Center at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York, United States
Cleveland Clinic (Data Collection Only), Cleveland, Ohio, United States
Fox Chase Cancer Center (Data Collection Only), Philadelphia, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
University of Washington (Data Collection Only), Seattle, Washington, United States
Name: Christopher Barker, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR